I don't think it's wrong to admit I want to outperform Steve Sjuggerud every year.
A little competition never hurt anyone, right?
Each month in my Retirement Millionaire newsletter, I come out with investment advice that I think will best serve my readers. Sometimes it's a tech stock I think will explode higher. Sometimes it's a beaten-down stock that folks are too pessimistic about. Or sometimes it's a "boring" blue-chip stock with a high dividend yield.
I've always had the philosophy that the advice I give to readers is the advice I'd give to my own mother.
But at the end of the day, I'm still competitive. I want the stocks I recommend to make folks a boatload of money. And I want my returns to beat Steve's returns, and Porter Stansberry's returns. (You can't put a price tag on bragging rights.)
I've always been extremely impressed with Steve's ability to understand big trends in the market. That's how he's made a name for himself. And it's how he consistently churns out huge winners. It shows in our annual Stansberry Report Card...
Steve's True Wealth newsletter had an average annualized return of 23.2%, while my Retirement Millionaire had an average annualized return of 22.4%. Porter's Stansberry's Investment Advisory wasn't too far behind at 18.5%.
While Steve gets to brag that he edged me out by 0.8 percentage points, I can't be upset. Folks who took all our advice made some big profits.
I'll be the first to admit, he won this last round. But our friendly "competition" is changing tonight...
I'm no longer "competing" against Steve and Porter. Instead, I'm relying on them for fantastic stock recommendations and research.
What I'm doing is simple... I'm essentially borrowing Steve and Porter's best ideas and showing you an entirely new way to trade them – for a chance at massive, triple-digit gains.
Back in November 2017, my team and I started live testing a new kind of options-trading strategy. It's a technique that has the potential to turn a small move (or no move) in a stock into triple-digit returns.
Over the past year, when Steve came out with a new recommendation, we'd read his analysis, think about where the stock could be going, and create a custom options trade for it. We'd do the same thing for Porter's best recommendations, and my own best ideas.
Again, Steve has a fantastic track record. He's great at picking winners. So I designed our custom trades to "juice" those winners within a short period of time.
After more than a year of live testing, the results have been fantastic. More than 65% of the trades we've recommended have closed for profits. And we've had an average annualized return of more than 600%.
We've made 117% trading an emerging markets fund... 201% on a boring HVAC business... 123% on a company that leads in human connection... and 181% on a steel fund.
All the stocks and funds have been recommended by Steve, Porter, or me over the past year. All the legwork was done for us. We were just crafting the custom options trades on the recommendations to reduce our risk and boost our upside potential.
You see, I'm no dummy. If you know some of the best stock pickers in the industry, use what they are doing and bet on it. That's what we're doing.
Tonight at 8 p.m. Eastern time, I'm revealing all the details about my new trading service based on this technique. It's called Advanced Options.
I believe the timing couldn't be better. Steve has been pounding the table for stocks to explode higher in the final innings of this bull market for a while now. And when Steve's this convinced that something will happen, he's usually right.
So when Steve comes out with a stock idea that could shoot up 50%-100% during the Melt Up, our options trade could potentially soar 300% or more.
And if stocks trade sideways for the next few months before the final surge, we'll still make a lot of money. One strategy we've been using consistently makes 50%-100% when stocks do not move at all.
Lastly, the great thing about this trading technique is that you don't need a massive portfolio to participate. Each trade will only cost a couple hundred bucks. But once you learn all the nuts and bolts of how it works, it will change the way you invest.
I'll explain everything in tonight's free event. For all the details, click here to tune in at 8 p.m. Eastern time.
Here's to our health, wealth, and a great retirement,
Dr. David Eifrig
Editor's note: Tonight, Doc is pulling back the curtain on his new trading service. It's designed to quickly turn any stock into a potential triple-digit winner... with less risk than buying shares outright. It can even help you profit from stocks that go nowhere. To learn how it works – and how to get in on special bonuses for early members – check out his free presentation at 8 p.m. Eastern time.
"When most folks hear the words 'stock options,' they think of risky bets on volatile moves in the stock market," Doc says. "Nothing could be further from the truth." Learn more about another simple way to use these powerful tools here: A Conservative Way to Generate 15% Returns on Your Portfolio.
"In addition to limiting risk, options can also improve your returns when used in the right market conditions,'" Doc writes. "That's a powerful combination." Read more about why now is the perfect time to get started with options right here.
I've built my track record on making big, contrarian predictions – but also on carefully planned trades. And as my colleague Ben Morris explains, avoiding one common mistake will help you maximize your gains in stocks...
THIS 'BIG PHARMA' STOCK IS SOARING
Today, we're taking another look at the bull market in health care stocks...
Longtime DailyWealth readers will remember Doc's bullish health care thesis. According to the Population Reference Bureau, the number of Americans older than 65 will double by 2060. And with age, more folks will need prescriptions, check-ups, and medical tests. Today's company is one of America's top drugmakers...
Eli Lilly (LLY) is a $126 billion pharmaceutical giant. The company makes well-known drugs like Alimta (lung-cancer treatment), Forteo (osteoporosis treatment), Humalog and Humulin (diabetes treatment), and Cymbalta (for depression and chronic pain). Eli Lilly is still thriving since our last check-in... It recently reported third-quarter revenue of more than $6 billion, up 7% from the same quarter in 2017. And more than a third of those sales came from new medicines... which shows this company is still innovating.
As today's chart shows, LLY's big rally has continued. The stock is up nearly 40% over the past year, recently hitting a new all-time high. As more Americans age, this health care giant should have more gains ahead...